Danielle Orozco Cosio, PhD’s Post

🧬 Unlocking RNA Targets: Advancing Drug Discovery with Cutting-Edge Simulations 💫 At Qubit Pharmaceuticals, we’ve made a breakthrough in computational drug design, tackling one of the biggest challenges in modern medicine: RNA-targeted therapeutics. By combining cutting-edge technologies like: 🔸 Lambda-ABF for precision binding affinity prediction 🔸 Tinker-HP for enhanced molecular dynamics 🔸 Advanced sampling techniques in combination with machine learning to capture complex RNA conformational changes …we're paving the way for faster, more accurate drug discovery, with unprecedented insights into RNA-small molecule interactions. RNA-targeting therapeutics also expand the druggable target space in the human genome from 0.2% to ~70%, offering an attractive alternative to reach traditionally undruggable proteins! 📰Our latest blog explores how our advanced methods open new possibilities for designing drugs to treat the most difficult diseases. The blog is based on a scientific publication, currently available as a preprint, showcasing these innovations. A special thanks to our partners Bpifrance, European Innovation Council and SMEs Executive Agency (EISMEA) , #FRANCE 2030, GENCI , Secrétariat général pour l'investissement, Région Île-de-France, and Sorbonne Université, as well as our investors Quantonation, XAnge & Omnes. And, of course, 👏massive congratulations👏 to the authors, Narjes A. , Chengwen Liu, Florent Hédin, Jérôme Hénin, Jay Ponder, Pengyu Ren, Jean-Philip Piquemal, Louis Lagardère, and Krystel El Hage, PhD El Hage for their remarkable work! 👉 Read more and discover how we're revolutionizing RNA drug discovery: https://loom.ly/SdIjUxA 👉 Straight to the preprint? Sure! https://loom.ly/Al9PcUU Pharmaceuticals and biotech companies seeking to unlock new treatment possibilities, let’s collaborate and make the next breakthrough together - Reach out to us today! #ComputationalChemistry #QuantumAidedDrugDesign #RNAtherapeutics #DrugDiscovery

✨ Want to know more about how our technology can solve the challenges of complex targets? Look below to learn more about how our teams address RNA through cutting edge simulations.

🌐𝐄𝐱𝐩𝐥𝐨𝐫𝐢𝐧𝐠 𝐁𝐫𝐞𝐚𝐤𝐭𝐡𝐫𝐨𝐮𝐠𝐡𝐬 𝐢𝐧 𝐑𝐍𝐀 𝐃𝐞𝐥𝐢𝐯𝐞𝐫𝐲 & 𝐎𝐥𝐢𝐠𝐨𝐧𝐮𝐜𝐥𝐞𝐨𝐭𝐢𝐝𝐞𝐬🌐 As the field of RNA therapeutics continues to evolve, we're witnessing transformative developments, particularly in RNA delivery systems. 📈 🔹 Non-Viral Systems dominate the landscape, driven by advances in technology and increasing regulatory support. Their growth surged during the COVID-19 pandemic and has since stabilized. At the same time, Non-viral Systems exhibit high entry and exit rates as researchers work to overcome challenges such as efficiency and specificity, leading to a dynamic pipeline 🔹 In contrast, Viral Systems are gaining much more cautious growth, The recent rise in interest and funding since 2022 shows a shift towards embracing the high-reward potential of these systems, despite safety and scalability concerns. Looking ahead, it’s clear that RNA delivery systems are set for further innovation, promising impactful therapies for unmet medical needs. Follow us at Hanson Wade Intelligence to stay tuned for more analysis like this! Our analysis was made possible with drug and clinical trial data from Beacon #RNATherapeutics #Oligonucleotides #Biotechnology #DrugDevelopment #PharmaInnovation #NonViralDelivery #ViralDelivery #BiotechTrends #TherapeuticDelivery #RNA

🌟 Explore How #AI is Accelerating RNA Therapeutic Discovery! Artificial intelligence is revolutionising the RNA therapeutics space, enabling unparalleled advancements in RNA structure analysis, target identification, and drug development precision. Join the RNA Therapeutics Conference to dive into these cutting-edge innovations. Check out the agenda now to see the sessions transforming RNA science: https://lnkd.in/eqtaB_NJ With experts from Sanofi, AstraZeneca, Sixfold Bioscience, and Korro Bio, Inc., you’ll gain insights into how AI-driven tools like deep learning and ML are enhancing RNA stability, tissue targeting, and therapeutic efficacy. This is the future of medicine—where RNA isn’t just a therapeutic candidate but also a target, unlocking breakthroughs in RNA-targeted small molecule discovery. Don’t miss out! Secure your ticket today to join this exciting conversation and learn how AI is propelling RNA therapeutics forward: https://lnkd.in/e2biKrfH #RNATherapeutics #mRNA #RNAi #Biotechnology #PharmaceuticalInnovation #DrugDelivery #GeneTherapy #HealthcareInnovation #Biopharma #PrecisionMedicine #RNAResearch #MedicalBreakthroughs #mRNATechnology #Therapeutics #NextGenMedicine #PharmaIndustry #RNAConference #BiotechConference #LifeSciences #Networking #Conference2025 #Biotech #SecureYourSpot

🔬 ReNAgade Therapeutics Emerges with $300M to Solve RNA Drug Delivery Challenge TL;DR: • Cambridge-based startup secures massive Series A funding • Developing revolutionary "all-in-one" RNA delivery platform • Strategic partnership with Orna Therapeutics & Merck • 100+ patents filed since 2021 • Team of 100 experts from Alnylam and Moderna While RNA therapeutics have transformed medicine, their impact remains limited primarily to liver diseases. ReNAgade Therapeutics is changing that. Led by CEO Amit Munshi, ReNAgade is developing advanced lipid nanoparticles to deliver RNA medicines to previously unreachable tissues and organs. Their platform integrates multiple cutting-edge technologies, including RNA editing tools and synthetic circular RNA applications. The company's potential has already attracted major players. A strategic collaboration with Orna Therapeutics caught Merck & Co.'s attention, resulting in a $100M investment. With funding from F2 Ventures and BioImpact, ReNAgade is positioned to accelerate development and achieve critical scale in today's challenging biotech landscape. 💭 What are your thoughts on the future of RNA delivery technologies? How might this breakthrough impact your work in biotech? #Biotech #RNATherapeutics #DrugDelivery #Innovation #BiotechNews #intelligencesimplified #pharma #biotech #biodatastudio

⏳ Less than 12 hours left to save £200 on your #RNATx2025 ticket! Have you secured your spot?: https://ow.ly/4WSL50TX3kg⏳ ✔️ Stay Ahead in Drug Delivery: Explore the latest challenges and breakthroughs in #RNA therapeutics, with insights into novel extra-hepatic delivery mechanisms. Discover how Roche’s brain-targeting strategies and Johnson & Johnson’s #LNP approaches are reshaping tissue targeting opportunities. ✔️ Collaborate & Connect: Engage with industry experts to exchange ideas and explore solutions to the biggest challenges, from optimising #biodistribution and #immunogenicity control to enhancing the durability of RNA therapeutic effects. ✔️ Expand Your Knowledge: Gain insights into computational innovations driving RNA drug discovery. Hear about #AI’s role in advancing tissue targeting, and learn from Sanofi, AstraZeneca and others about predictive models, AI for RNA design, and cutting-edge deep learning methodologies. ✔️ Insightful Regulatory Perspectives: Hear from senior regulatory experts at Medicines and Healthcare products Regulatory Agency and Moderna as they discuss the support available for pioneering RNA therapies and strategies to propel R&D via RNA platforms. 🔬 Don’t miss this chance to connect with life sciences leaders and learn about the latest in RNA therapeutics. Reserve your spot here: https://ow.ly/4WSL50TX3kg ✨ #RNATherapeutics #mRNA #RNAi #Biotechnology #PharmaceuticalInnovation #DrugDelivery #GeneTherapy #HealthcareInnovation #Biopharma #PrecisionMedicine #RNAResearch #MedicalBreakthroughs #mRNATechnology #Therapeutics #NextGenMedicine #PharmaIndustry #RNAConference #BiotechConference #LifeSciences #Networking #Conference2025 #Biotech #SecureYourSpot

⏳ Less than 12 hours left to save £200 on your #RNATx2025 ticket! Have you secured your spot?: https://ow.ly/4WSL50TX3kg⏳ ✔️ Stay Ahead in Drug Delivery: Explore the latest challenges and breakthroughs in #RNA therapeutics, with insights into novel extra-hepatic delivery mechanisms. Discover how Roche’s brain-targeting strategies and Johnson & Johnson’s #LNP approaches are reshaping tissue targeting opportunities. ✔️ Collaborate & Connect: Engage with industry experts to exchange ideas and explore solutions to the biggest challenges, from optimising #biodistribution and #immunogenicity control to enhancing the durability of RNA therapeutic effects. ✔️ Expand Your Knowledge: Gain insights into computational innovations driving RNA drug discovery. Hear about #AI’s role in advancing tissue targeting, and learn from Sanofi, AstraZeneca and others about predictive models, AI for RNA design, and cutting-edge deep learning methodologies. ✔️ Insightful Regulatory Perspectives: Hear from senior regulatory experts at Medicines and Healthcare products Regulatory Agency and Moderna as they discuss the support available for pioneering RNA therapies and strategies to propel R&D via RNA platforms. 🔬 Don’t miss this chance to connect with life sciences leaders and learn about the latest in RNA therapeutics. Reserve your spot here: https://ow.ly/4WSL50TX3kg ✨ #RNATherapeutics #mRNA #RNAi #Biotechnology #PharmaceuticalInnovation #DrugDelivery #GeneTherapy #HealthcareInnovation #Biopharma #PrecisionMedicine #RNAResearch #MedicalBreakthroughs #mRNATechnology #Therapeutics #NextGenMedicine #PharmaIndustry #RNAConference #BiotechConference #LifeSciences #Networking #Conference2025 #Biotech #SecureYourSpot

Join me at this panel discussion to talk about AI in genomics and drug discovery, and the role of women leaders in this field.

🔬 Orbital Therapeutics Raises Record-Breaking $270M Series A TL;DR: • Largest biotech Series A of the year • Focus: Next-gen RNA technology development • Timeline: IND filing planned within 2-4 years • Key partnership with Beam Therapeutics Despite current market headwinds, Orbital Therapeutics has secured massive investor confidence, demonstrating the enduring potential of innovative RNA therapeutics. The Cambridge-based company is targeting applications beyond traditional RNA limitations, including vaccines, protein replacement, and treatments for autoimmune conditions and cancer. Led by CEO Giuseppe Ciaramella and industry veteran John Maraganore (former Alnylam CEO), Orbital is positioned to expand the reach of RNA-based drugs beyond liver-targeted therapies - a significant limitation of current technologies. Strategic moves include: • CircBio acquisition for circular RNA IP • Stanford University delivery tech licensing • Dual presence in Cambridge and South SF • Partnership with Beam Therapeutics Funding led by Arch Venture Partners, with participation from a16z, Newpath Partners, and others. 💭 What are your thoughts on the future of RNA therapeutics? How might this funding reshape the biotech landscape? #Biotech #RNATherapeutics #VentureCapital #Innovation #BiotechNews #intelligencesimplified #pharma #biotech #biodatastudio

Radar Therapeutics Completes $13.4M Seed Financing To Advance Smart Programmable Medicines Learn more & get our take 👇 https://lnkd.in/g5DfBuay “With Radar’s technology, we can now precisely alter the biology of the cell, delete harmful cells, or potentially reprogram cells for autoimmune diseases. This has the potential to enable a new generation of safer, more durable, and effective mRNA therapeutics for applications beyond vaccines.” — Jim Collins, Ph.D., Co-Founder at Radar Therapeutics “Creating genetic expression-regulation systems that operate at the level of translation while being programmable to ensure compatibility with next-generation mRNA-based medicines has been a long-lived dream.” — Xiaojing Gao, Ph.D., Associate Professor of Chemical Engineering at Stanford University and Radar Co-Founder “Like a safety switch, our payload is always off, and only gets turned on in the right cell. We can selectively write a function into any cell type. Programmable mRNA-based therapies have the potential to be in vivo, scalable, and modular, to improve patient access.” — Sophia Lugo, CEO & Co-Founder at Radar Therapeutics #biotech #funding #SoHCNews